This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The TACT2 study was designed to replicate the results of a previous trial, TACT , which reported in 2012 that chelation reduced subsequent cardiovascular events after a heartattack. and Canadian patients with diabetes and a history of heartattack,” said Gervasio A. and Canada.
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heartattack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. About 32% had Type 2 diabetes.
milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heartattack or stroke within three months of a prior heartattack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.
The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heartattack or stroke within three months of a prior heartattack, according to research presented at ACC.24, 24, the American College of Cardiology Annual Annual Scientific Session.
The fear of having another heartattack was a major ongoing stressor for heartattack survivors, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024, held Nov. 16–18, 2024, in Chicago.
A new, rapid blood test that spots whether people are having a heartattack could improve the treatment of people presenting with chest pain at emergency departments, according to late-breaking research presented in a Hot Line Session Sept. 2 at this year's ESC Congress 2024.
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heartattack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
tim.hodson Mon, 11/18/2024 - 10:55 Nov. Patient Demographics: Patients on APT had a higher rate of coronary artery disease (70% vs. 42%), previous heartattacks (36% vs. 16%), and peripheral artery disease (15% vs. 11%). For more information, please visit anthostherapeutics.com.
Heartattack risk almost doubles in the first year after a stroke or when combined with a tear in a neck artery wall; however, a tear without a stroke does not seem to raise heartattack risk, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2024.
Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heartattacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect.
milla1cf Wed, 02/14/2024 - 18:21 February 14, 2024 — Efemoral Medical , developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration ( FDA ) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions (..)
Sumeet Chugh, MD, shown at work in his Cedars-Sinai laboratory, is the recipient of the American College of Cardiology 2024 Distinguished Scientist Award-Clinical Domain. Although “sudden cardiac arrest” and “heartattack” are often mistaken to be the same, the conditions are quite different. Photo by Cedars-Sinai.
The findings call into question the routine use of beta blockers for all patients following a heartattack, which have stood as a mainstay of care for decades. Approximately 50% of heartattack survivors do not experience heart failure.
hospitals meet the national average of mortality and payment rates used to calculate value of care for heartattack patients, according to CMS data published Oct. 30, 2024. The majority of U.S.
The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heartattack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), 24), being held April 6-8 in Atltanta, GA.
DALLAS, May 14, 2024 — Living with a chronic medical condition after surviving a heartattack or stroke may come with additional health and personal care needs. Often survivors must rely on a family member or close friend to help. However, there’s a.
milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heartattack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.
(RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heartattack detection. milla1cf Mon, 04/22/2024 - 15:05 April 22, 2024 — At the annual American College of Cardiology conference ( ACC.24 Dohad , MD, as principal investigator.
CaRi-Plaque builds on Caristoscore CaRi-Hearttechnology, which a Lancet 2024 study proved can reveal hidden, high-risk markers of CAD progression predicting heartattacks up to a decade before they strike. For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action.
The study focused on patients who underwent PCI for acute coronary syndromes (ACS)—life-threatening conditions which include heartattacks and chest pain caused by decreased blood flow to the heart—with stents containing drugs to prevent further plaque buildup.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. Coronary inflammation is a crucial piece of the puzzle in predicting heartattack risk.
CAD is estimated to be responsible for one heartattack every 40 seconds and one out of every five deaths. 2024 Apr, 83 (13_Supplement) 2320. In the U.S., 1 Many of the estimated 18 million adults in the U.S. and 315 million people globally living with CAD either have no symptoms or symptoms that go unrecognized.
Youth with high blood pressure are nearly four times more likely to be at long-term risk of serious heart conditions including stroke and heartattack, according to a new study. The research, led by McMaster University, will be presented at the Pediatric Academic Societies (PAS) 2024 Meeting, held May 2–6 in Toronto.
Getty Images milla1cf Thu, 01/25/2024 - 20:44 January 25, 2024 — Agepha Pharma , a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment ( LODOCO – colchicine, 0.5 mg tablets for therapeutic intervention. In June 2023, the U.S.
These new findings suggest that people with high-risk plaques that are likely to rupture could benefit from the procedure as a pre-emptive measure rather than waiting for a heartattack or other severe reduction in blood flow to occur. During PCI, an operator inserts a stent into a blocked artery through a catheter in the groin or arm.
milla1cf Wed, 04/24/2024 - 19:01 April 24, 2024 — Hello Heart , a digital leader in preventive heart health, today announced results from its latest study observing the benefits of scalable, accessible digital health tools for a growing senior population. Eighty percent of heartattacks and strokes are preventable.
Pocket-Sized Kardia 12L ECG System milla1cf Tue, 06/25/2024 - 18:55 June 25, 2024 — AliveCor , the global leader in AI -powered cardiology, today announced the U.S. This is the world’s first AI that can detect life-threatening cardiac conditions, including heartattacks, using a reduced leadset.
All patients who have had a heartattack are typically treated using beta blockers. According to a Swedish study conducted earlier in 2024, this drug is unlikely to be needed for those heart patients who have normal pumping ability.
Using artificial intelligence (AI) to aid clinical decision making in identifying and managing myocardial infarction (MI; heartattack) in patients presenting to the emergency department (ED) with suspected cardiac conditions does not improve cardiovascular outcomes. 2 Sept.).
tim.hodson Thu, 12/05/2024 - 11:59 Dec. 4, 2024 – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 million. This funding round was led by global software investor Insight Partners and joined by Battery Ventures with participation from pre-existing investors.
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.
milla1cf Sun, 04/07/2024 - 18:20 April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated triglycerides, also known as hypertriglyceridemia , putting them at an increased risk for heartattacks and stroke.
Image courtesy: Getty Images christine.book Thu, 02/08/2024 - 15:53 February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association ’s International Stroke Conference , ISC 2024 , shed light on the use of artificial intelligence ( AI ) to help guide treatment decisions for stroke patients.
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heartattack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.
Elucid’s PlaqueIQ is the first and only histology-validated FDA-cleared software to non-invasively quantify and characterize non-calcified plaque and its components such as lipid-rich necrotic core (LRNC), giving potential insights into high-risk plaques, key drivers of risk of heartattack and stroke.
The answer is pretty simple, but most people get this wrong, and doing so increases their future risk of heartattack and strokes. 2024 Nov;81(11):2329-2339. ” This is one of the most common questions I get as a cardiologist. High blood pressure is the leading cause of preventable death worldwide 1. N Engl J Med.
Getty Images milla1cf Tue, 04/16/2024 - 12:43 April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention , or PCI, a minimally invasive procedure to unclog the arteries that feed the heart. The results are published in PLOS ONE.
mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. , The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported.
KAI 12L is the world's first AI to detect 35 cardiac determinations, including heartattacks, using a reduced leadset. In accordance with the AMA semi-annual early release schedule, the new codes will be effective January 1st, 2025 and published in the 2025 CPT Code book. Kardia 12L ECG System is battery-operated, weighs just 0.3
3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heartattack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 milligrams per liter (mg/L) are linked to increased risk of heartattacks or risk of a repeat heartattack.23 4 In the U.S.
milla1cf Thu, 06/20/2024 - 19:40 June 20, 2024 — A programing algorithm, being tested by HonorHealth Research Institute for those patients with new or recently installed pacemakers, is designed so the device not only provides a steady heartbeat, but also controls high blood pressure. You just turn it on, and it works,” Dr.
Getty Images milla1cf Thu, 05/16/2024 - 15:37 May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced adverse effects of economic and social conditions that influence individual and group differences in health status, known as social determinants of health.
Many studies have shown that people who engage in more physical activity are healthier and have fewer heartattacks and strokes than people who engage in less. This is equally true for people who have previously had a heartattack or a stroke or have heart failure or are at risk for cardiovascular disease.”
Kenneth Chan, MBBS, Academic Clinical Research Fellow in the Division of Cardiovascular Medicine at Oxford University Hospitals (UK) will receive the 2024 SCCT Clinical Trials and Registries Award (CTRA) at the opening session of the Society’s 19th Annual Scientific Meeting (SCCT2024) on Friday, July 19 in Washington, DC.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content